×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Company: Bristol Myers Squibb — Ozanimod and S1P Modulation
company
796 words
KG: ent-comp-a129b908
Contents
Bristol Myers Squibb — Ozanimod and S1P Modulation
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Crunchbase
Wikipedia
Related Hypotheses (27)
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.88
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.78
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.77
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.71
Membrane Cholesterol Gradient Modulators
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Extracellular Matrix Stiffness Modulation
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
Lysosomal Positioning Dynamics Modulation
Score: 0.69
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
RNA Granule Nucleation Site Modulation
Score: 0.66
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.65
Serine/Arginine-Rich Protein Kinase Modulation
Score: 0.62
pg 1/2
Next →
Related Analyses (18)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · completed
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 13 more
Related Experiments (1)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
See Also (15)
Alpha-Synuclein PET Imaging and Biomarker Advances
biomarker · Pages share 3 hypotheses
Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)
biomarker · Pages share 3 hypotheses
Imaging Biomarkers for Corticobasal Syndrome and Progre
biomarker · Pages share 3 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 3 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
Multi-Analyte Biomarker Panel for Parkinson's Disease D
biomarker · Pages share 3 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease
biomarker · Pages share 3 hypotheses
Polygenic Risk Score Integration Panel for Alzheimer's
biomarker · Pages share 3 hypotheses
CSF and Blood Biomarkers in Progressive Supranuclear Pa
biomarker · Pages share 3 hypotheses
AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integrat
biomarker · Pages share 3 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.